| Literature DB >> 34755759 |
Mariluce Rodrigues Marques Silva1,2, Waleska Maria Almeida Barros1,2,3, Mayara Luclécia da Silva2,3, José Maurício Lucas da Silva2,3, Ana Patrícia da Silva Souza1,2, Ana Beatriz Januário da Silva1,2, Matheus Santos de Sousa Fernandes1, Sandra Lopes de Souza1, Viviane de Oliveira Nogueira Souza4,5.
Abstract
Vitamin D is a fat-soluble vitamin that plays a role not only in calcium homeostasis, but also in several other functions, including cell growth and immune functions, and is considered a neurosteroid. Vitamin D deficiency is highly prevalent worldwide and has been suggested to be associated with an increased risk of emotional disorders. Therefore, the association between vitamin D levels and psychophysiological disorders, such as depression, anxiety, and mood, has been investigated. To list these variables, a bibliographical literature research was conducted in the MEDLINE/PubMed, Web of Science, Scopus, Science Direct and PsycINFO databases, between November and December 2020, with no year limits of publication. The studies involved humans aged between 18 and 59 years without associated diseases. This review presents evidence of the main variables involved in this association, main tools used to verify these variables, and methods used to verify circulating vitamin D levels in populations. Most studies have indicated that the main psychophysiological variables involved with vitamin D levels are depression and anxiety followed by mood, and an association has been observed between increased serum vitamin D levels and reduction in symptoms of depression, anxiety, and mood, and there is a heterogeneity of methods for assessing vitamin D. More studies are clearly needed to improve our understanding of their role in modulating the psychophysiological aspects of vitamin D levels.Entities:
Mesh:
Substances:
Year: 2021 PMID: 34755759 PMCID: PMC8552952 DOI: 10.6061/clinics/2021/e3155
Source DB: PubMed Journal: Clinics (Sao Paulo) ISSN: 1807-5932 Impact factor: 2.365
Critical appraisal results for included studies using the Joanna Briggs Institute for verification of cross-sectional analytical studies.
| Study | Q1 | Q2 | Q3 | Q4 | Q5 | Q6 | Q7 | Q8 |
|---|---|---|---|---|---|---|---|---|
| Avinun; Romer e Israel 2020 | Y | Y | Y | Y | N | U | Y | Y |
| Casseb et al. 2019 | U | Y | Y | Y | Y | Y | Y | Y |
| Pooyan et al. 2018 | Y | Y | Y | Y | N | U | Y | Y |
| Kim et al. 2016 | Y | Y | Y | Y | Y | Y | U | Y |
| Bicíková et al. 2015 | Y | U | Y | Y | N | U | Y | Y |
| Huang et al. 2014 | Y | Y | Y | Y | Y | Y | Y | Y |
| Atram; Ragunath e Kannan 2020 | U | Y | Y | Y | N | U | Y | Y |
| Altinbas et al. 2019 | Y | Y | Y | Y | Y | Y | Y | Y |
| Von Känel et al. 2015 | Y | Y | Y | Y | Y | Y | Y | Y |
Y - Yes, N - No, U - Unclear. Q1: Have the criteria for inclusion in the sample clearly defined?; Q2: Were the study subjects and the setting described in detail?; Q3: Was the exposure measured in a valid and reliable way?; Q4: Were objective, standard criteria used for measurement of the condition?; Q5: Were Confounding factors identified?; Q6: Were strategies to deal with confounding factors stated?; Q7: Were the outcomes measured in a valid and reliable way?; Q8: Was appropriate statistical analysis used?
Critical appraisal results for included studies using the Joanna Briggs Institute for verification of randomized clinical trials.
| Study | Q1 | Q2 | Q3 | Q4 | Q5 | Q6 | Q7 | Q8 | Q9 | Q10 | Q11 | Q12 | Q13 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dean et al. 2011 | Y | Y | N | Y | Y | Y | Y | Y | Y | Y | U | Y | Y |
| Lansdowne e Provost 1998 | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | U | Y | Y |
| Choukri et al. 2018 | Y | U | N | Y | U | Y | Y | Y | Y | Y | U | Y | Y |
| Williams et al. 2016 | Y | U | N | Y | U | Y | Y | Y | Y | Y | Y | Y | Y |
Y - Yes, N - No, U - Unclear. Q1: Was true randomization used for assignment of participants to treatment groups?; Q2: Was allocation to treatment groups concealed?; Q3: Were treatment groups similar at the baseline?; Q4: Were participants blind to treatment assignment?; Q5: Were those delivering treatment blind to treatment assignment?; Q6: Were outcomes assessors blind to treatment assignment?; Q7: Were treatment groups treated identically other than the intervention of interest?; Q8: Was follow up complete and if not, were differences between groups in terms of their follow up adequately described and analyzed?; Q9: Were participants analyzed in the groups to which they were randomized?; Q10: Were outcomes measured in the same way for treatment groups?; Q11: Were outcomes measured in a reliable way?; Q12: Was appropriate statistical analysis used?; Q13: Was the trial design appropriate, and any deviations from the standard RCT design (individual randomization, parallel groups) accounted for in the conduct and analysis of the trial?
Critical appraisal results for included studies using the Joanna Briggs Institute for verification of cohort studies.
| Study | Q1 | Q2 | Q3 | Q4 | Q5 | Q6 | Q7 | Q8 | Q9 | Q10 | Q11 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Black et al. 2014 | U | U | Y | Y | Y | Y | Y | Y | Y | U | Y |
Y - Yes, N - No, U - Unclear. Q1: Were the two groups similar and recruited from the same population?; Q2: Were the exposures measured similarly to assign people to both exposed and unexposed groups?; Q3: Was the exposure measured in a valid and reliable way?; Q4: Were confounding factors identified?; Q5: Were strategies to deal with confounding factors stated?; Q6: Were the groups/participants free of the outcomes at the start of the study (or at the moment of exposure)?; Q7: Were the outcomes measured in a valid and reliable way?; Q8: Was the follow up time reported and sufficient to be long enough for outcomes to occur?; Q9: Was follow up complete, and if not, were the reasons to loss to follow up described and explored?; Q10: Were strategies to address incomplete follow up utilized?; Q11: Was appropriate statistical analysis used?
Critical appraisal results for included studies using the Joanna Briggs Institute for checking case control studies.
| Study | Q1 | Q2 | Q3 | Q4 | Q5 | Q6 | Q7 | Q8 | Q9 | Q10 |
|---|---|---|---|---|---|---|---|---|---|---|
| Hashemi et al. 2017 | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y |
Y - Yes, N - No, U - Unclear. Q1: Were the groups comparable other than the presence of disease in cases or the absence of disease in controls?; Q2: Were cases and controls matched appropriately?; Q3: Were the same criteria used for identificatio of cases and controls?; Q4: Was exposure measured in a standard, valid and reliable way?; Q5: Was exposure measured in the same way for cases and controls?; Q6: Were confounding factors identified?; Q7: Were strategies to deal with confounding factors stated?; Q8: Were outcomes assessed in a standard, valid and reliable way for cases and controls?; Q9: Was the exposure period of interest long enough to be meaningful?; Q10: Was appropriate statistical analysis used?
Figure 1Flowchart of bibliographic research and selection of studies for this systematic review according to PRISMA.
Descriptions of the studies included in the systematic review.
| Author, year | Type of Study | Sample, age | Objective | Variables analyzed | Measuring instruments | Parameters of vitamin D | Main Results |
|---|---|---|---|---|---|---|---|
| 01° | Cross sectional | n=522 | Investigate the association between polygenic vitamin D scores and neuroticism personality traits. | Personality; | Personality inventory; | __ | ↑ GWAS-derived polygenic scores of associated vitamin D serum concentrations ↓ neuroticism |
| 02° | Cross sectional | n=36 | Investigate the relationship between vitamin D levels, biochemical profile, and symptoms of depression and anxiety in healthy individuals. | Symptoms of depression | Beck (BDI) | Insufficient: <40 ng/mL | ↓ 25 (OH) D3 levels associated with detrimental effects on the biochemical profile, including ↑ glucose levels, triglycerides, and triglyceride/HDL ratio |
| 03° | Cross sectional | n=265 | Examine the effects of polymorphisms on the GC gene, which encodes VDBP | Anthropometry Body composition Dietary intake | Depression Anxiety | __ | This study demonstrated that an HP/LF diet can interact with the VDBP genotype to moderate the risk of depression |
| 04° | Cross sectional | n=14,104 | Examine the correlation between vitamin D level and HRQoL in adults | Serum level of 25-hydroxyvitamin D | HRQOL survey (assesses quality of life, including depression and anxiety) | __ | Vitamin D level was not significantly associated with EuroQol-5 dimensions, except for depression and anxiety problems |
| 05° | Cross sectional | n=126 | Investigate association of vitamin D levels in depression, anxiety, and control groups | Depression and anxiety | Neuropsychiatric Interview (MINI Sheehan et al. 1998) | Suitable: 30-40 ng/mL | Significantly lower levels of calcidiol were found in men and women with depression |
| 06° | Cross sectional | n=500 | To assess the associations between vitamin D concentrations in early pregnancy and symptoms of depression and antepartum anxiety and their potential modifiers. | Serum level of 25-hydroxyvitamin D Symptoms of depression and anxiety | Depression, Anxiety and Stress Scales (DASS-21) Patient Health Questionnaire Depression Module (PHQ-9) | Insufficient: ≤32 ng/mL | A decrease of 1 ng/mL in 25 [OH] D was associated with greater anxiety and depression scores Participants with the lowest concentrations of 25 [OH] D (quartile 4: 25 [OH] D <28.9 ng/mL) had 1.11 higher PHQ-9 scores compared with participants with the highest concentrations of 25 [OH] D (quartile 1: 25 [OH] D ≥39.5 ng/mL. |
| 07° | Cohort | n=2,125 | Examine the associations between vitamin D concentrations and depressive symptoms. | Serum level of 25-hydroxyvitamin D | Depression, Anxiety and Stress Scales of 21 self-reported items (DASS-21). | Sufficient: ≥75 nmol/L | There was a cross-sectional association between vitamin D concentrations and symptoms of depression, but not anxiety and stress. |
| 08° | Clinical trial | n=128 | Check if vitamin D supplementation influences cognition and emotion compared with placebo. | Working memory | Task N-Back | Ctoff point used for failure: 50 nmol/L | Results: N/S, despite ↑ in vitamin D levels. |
| 09° | Clinical trial | n=44 students | Investigate whether vitamin D3 improves mood in healthy individuals during winter. | Humor | Programming scale of positive and negative effects (PANAS) | __ | Vitamin D3 levels have a positive effect on mood and vary significantly between seasons. Results imply a link between the hormone and seasonal mood swings |
| 10° | Cross-sectional | n=100 men | To understand the correlation between vitamin D deficiency, incidence of depression and anxiety and its influence on the academic performance of university dental students | Symptoms of depression and anxiety | 25 (OH) D assay using Elisa DiaSorin S.p.A (Saluggia, Italy) | Insufficiency: 25 (OH) D <20 ng/mL. | Vitamin D deficiency was positively correlated with anxiety symptoms |
| 11° | Cross-sectional | n=96 health professionals | To investigate the impact of vitamin D levels on the severity of anxiety and depression in the operating room and ICU staff. | Symptoms of depression and anxiety | Measurement of vitamin D levels by (Electrochemiluminescence) Hospital Anxiety and Depression Scale (HADS) | Insufficiency: 25 (OH) D3 <20 ng/mL | ↓ vitamin D levels in the operating room and ICU staff had a negative impact on anxiety and depression levels |
| 12° | Clinical trial | n=152 young adult women | To test the causal effects of vitamin D3 supplementation on depression in a large non-clinical sample of pre-menopausal women over a 6-month period. | Depression | CES-D (symptoms of depression) | Levels <20 ng/mL have been established for insufficiency. | N/S the effects of a single monthly dose of vitamin D3 supplementation during autumn and winter on depression and other mood outcomes in healthy premenopausal women. |
| 13° | Cross Sectional | n=126 pregnant women | Check if lower levels of vitamin D during pregnancy would be associated with higher depression symptom scores during pregnancy and 6-8 weeks after delivery. | Depression | Beck Depression Inventory | Sufficiency: >20 ng/mL | ↓ Vitamin D levels in early pregnancy are associated with ↑ depressive symptom scores in early and late pregnancy |
| 14° | Case Control | n=45 female non-depressed medical science students with some degrees of stress and anxiety 45 controls without depression, stress, and anxiety | Investigate the relationship between stress and anxiety with vitamin D and serum TAC | Depression and anxiety | Depression, Anxiety and Stress Status Questionnaire (DASS) | Insufficient: 25-74 nM/L | Low levels of vitamin D may be associated with increased stress and anxiety. |
| 15° | Cross sectional | n=380 | To investigate the relationship between vitamin D status, severity, and dimension of depressive symptoms in hospitalized patients with psychiatric depression | Severity of depression | Hospital Anxiety and Depression Scale | Deficiency: <50 nmol/L | Vitamin D deficiency: ↑ score on the HADS-D scale and on an anhedonia symptom factor. Vitamin D deficiency: ↑score on the BDI-II scale. |
DNA- Deoxyribonucleic acid; Nucleic Acid; GWAS- Genome-wide association study (methodology used to detect associations between genetic variations); BDI- Beck Depression Inventory; N/S- Not significant; GC- The main transport protein responsible for the transfer of calcitriol to the target neurons; VDBP- Vitamin D binding protein; LDL- Low density lipoprotein; HDL- High density lipoprotein; HP- high protein; Low-fat LF; HRQOL- Health-related quality of life; HADS- Hospital Anxiety and Depression Scale; DASS-21- Depression, Anxiety and Stress Scales of 21 self-reported items; PANAS- Scale of programming of positive and negative effects; EPDS-Edinburgh Postnatal Depression Scale; TAC- Total antioxidant capacity.